Lymphocyte transformation by Pim-2 is dependent on nuclear factor-κB activation

被引:81
作者
Hammerman, PS
Fox, CJ
Cinalli, RM
Xu, A
Wagner, JD
Lindsten, T
Thompson, CB
机构
[1] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA
[3] Haverford Coll, Dept Biol, Haverford, PA 19041 USA
关键词
D O I
10.1158/0008-5472.CAN-04-2284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pim-2 is a transcriptionally regulated oncogenic kinase that promotes cell survival in response to a wide variety of proliferative signals. Deregulation of Pim-2 expression has been documented in several human malignancies, including leukemia, lymphoma, and multiple myeloma. Here, we show that the ability of Pim-2 to promote survival of cells is dependent on nuclear factor (NF)-kappaB activation. Pim-2 activates NF-kappaB-dependent gene expression by inducing phosphorylation of the oncogenic serine/threonine kinase Cot, leading to both augmentation. of IkappaB kinase activity and a shift in nuclear NF-kappaB from predominantly p50 homodimers to p50/p65 heterodimers. Blockade of NF-kappaB function eliminates Pim-2-mediated survival in both cell lines and primary cells, and both Cot phosphorylation and expression are required for the prosurvival effects of Pim-2. Although Pim-2 cooperates with Myc to promote growth factor-independent cell proliferation, this feature is abrogated by NF-kappaB blockade. The ability of Pim-2 to serve as an oncogene in vivo depends on sustained NF-kappaB activity. Thus, the transcriptional induction of Pim-2 initiates a novel NF-kappaB activation pathway that regulates cell survival.
引用
收藏
页码:8341 / 8348
页数:8
相关论文
共 44 条
  • [1] Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
  • [2] Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc
    Allen, JD
    Verhoeven, E
    Domen, J
    vanderValk, M
    Berns, A
    [J]. ONCOGENE, 1997, 15 (10) : 1133 - 1141
  • [3] THE HUMAN PROTOONCOGENE PRODUCT P33PIM IS EXPRESSED DURING FETAL HEMATOPOIESIS AND IN DIVERSE LEUKEMIAS
    AMSON, R
    SIGAUX, F
    PRZEDBORSKI, S
    FLANDRIN, G
    GIVOL, D
    TELERMAN, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) : 8857 - 8861
  • [4] NF-κB1 p105 negatively regulates TPL-2 MEK kinase activity
    Beinke, S
    Deka, J
    Lang, V
    Belich, MP
    Walker, PA
    Howell, S
    Smerdon, SJ
    Gamblin, SJ
    Ley, SC
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (14) : 4739 - 4752
  • [5] TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105
    Belich, MP
    Salmerón, A
    Johnston, LH
    Ley, SC
    [J]. NATURE, 1999, 397 (6717) : 363 - 368
  • [6] Castro A, 1999, J IMMUNOL, V162, P1261
  • [7] CHANG CC, 1995, MOL CELL BIOL, V15, P5180
  • [8] Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control
    Chu, ZL
    McKinsey, TA
    Liu, L
    Gentry, JJ
    Malim, MH
    Ballard, DW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) : 10057 - 10062
  • [9] A molecular compendium of genes expressed in multiple myeloma
    Claudio, JO
    Masih-Khan, E
    Tang, HC
    Gonçalves, J
    Voralia, M
    Li, ZH
    Nadeem, V
    Cukerman, E
    Francisco-Pabalan, O
    Liew, CC
    Woodgett, JR
    Stewart, AK
    [J]. BLOOD, 2002, 100 (06) : 2175 - 2186
  • [10] Delineation of prognostic biomarkers in prostate cancer
    Dhanasekaran, SM
    Barrette, TR
    Ghosh, D
    Shah, R
    Varambally, S
    Kurachi, K
    Pienta, KJ
    Rubin, MA
    Chinnaiyan, AM
    [J]. NATURE, 2001, 412 (6849) : 822 - 826